1. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs
- Author
-
Maria Demarco, Noorie Hyun, Olivia Carter-Pokras, Tina R. Raine-Bennett, Li Cheung, Xiaojian Chen, Anne Hammer, Nicole Campos, Walter Kinney, Julia C. Gage, Brian Befano, Rebecca B. Perkins, Xin He, Cher Dallal, Jie Chen, Nancy Poitras, Marie-Helene Mayrand, Francois Coutlee, Robert D. Burk, Thomas Lorey, Philip E. Castle, Nicolas Wentzensen, and Mark Schiffman
- Subjects
HPV genotype ,HPV outcome, Clearance ,Progression ,Persistence ,Medicine (General) ,R5-920 - Abstract
Background: HPV testing is replacing cytology for cervical cancer screening because of greater sensitivity and superior reassurance following negative tests for the dozen HPV genotypes that cause cervical cancer. Management of women testing positive is unresolved. The need for identification of individual HPV genotypes for clinical use is debated. Also, it is unclear how long to observe persistent infections when precancer is not initially found. Methods: In the longitudinal NCI-Kaiser Permanente Northern California Persistence and Progression (PaP) Study, we observed the clinical outcomes (clearance, progression to CIN3+, or persistence without progression) of 11,573 HPV-positive women aged 30–65 yielding 14,158 type-specific infections. Findings: Risks of CIN3+ progression differed substantially by type, with HPV16 conveying uniquely elevated risk (26% of infections with seven-year CIN3+ risk of 22%). The other carcinogenic HPV types fell into 3 distinct seven-year CIN3+ risk groups: HPV18, 45 (13% of infections, risks >5%, with known elevated cancer risk); HPV31, 33, 35, 52, 58 (39%, risks >5%); and HPV39, 51, 56, 59, 68 (23%, risks
- Published
- 2020
- Full Text
- View/download PDF